Legend Biotech to Present LB2102 Phase 1 Data at ASCO; CARVYKTI Updates
Legend Biotech announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including preliminary Phase 1 data for LB2102, its investigational DLL3-targeted CAR-T therapy for relapsed or refractory small-cell lung cancer and large-cell neuroendocrine carcinoma. The data highlights a manageable safety profile and early evidence of clinical activity, marking progress in extending CAR-T approaches into solid tumors. Additionally, new analyses of CARVYKTI® from the CARTITUDE-4 study and on immune effector cell-associated enterocolitis will be presented, reinforcing its robust clinical profile in multiple myeloma. The company will also host an investor relations event during ASCO.
Key Highlights
- Preliminary Phase 1 data for LB2102 in relapsed/refractory SCLC/LCNEC to be presented at ASCO.
- LB2102 data shows manageable safety profile and early evidence of clinical activity in solid tumors.
- New data from the CARTITUDE-4 study on CARVYKTI® to be featured in a poster presentation.
- A multi-study analysis on immune effector cell-associated enterocolitis (IEC-EC) for CARVYKTI® will also be presented.
- CARVYKTI® is commercially available in 18 countries globally.
- Over 10,000 patients have been treated with CARVYKTI® to date.
- Legend Biotech will host an investor relations event on May 31, 2026, at 6:15 p.m. CT.
Price Impact
More from LEGN